Bank of America just raised its EUR/USD forecast
Investing.com -- Shares of Niagen Bioscience Inc (NASDAQ:NAGE) climbed 3.5% after the company announced results from a clinical study published in Aging Cell, which demonstrated the safety and efficacy of their patented nicotinamide riboside ingredient, Niagen®, in individuals with Werner syndrome (WS). The study marks the first of its kind to show such results in WS patients, a rare genetic disorder characterized by rapid aging.
The double-blind, placebo-controlled study revealed that daily supplementation with Niagen significantly raised blood NAD+ levels by about 140% and improved multiple clinical markers of cardiovascular and skin health in WS individuals. These findings are particularly noteworthy as WS, which affects 1 in 380,000 to 1 in 1,000,000 people globally, is caused by mutations that lead to accelerated cellular aging.
Niagen Bioscience’s focus on rare, age-related diseases has been further emphasized by the U.S. Food and Drug Administration’s (FDA) Orphan Drug Designation and Rare Pediatric Disease Designation for Niagen in treating Ataxia Telangiectasia (AT). This underscores the urgent need and potential value of Niagen in rare disease populations.
The clinical trial, which lasted 52 weeks, included a crossover with participants receiving either 1,000 mg/day of Niagen or a placebo for 26 weeks before switching treatments. The study not only showed a robust increase in NAD+ levels but also reported significant improvements in arterial stiffness and a cardioprotective lipid shift. Additionally, Niagen supported wound healing by reducing skin ulcer size, and no moderate or severe adverse events were reported, highlighting its clinical safety profile.
The positive outcomes of this study support further investigation into NAD+ augmentation as a therapeutic strategy in rare progeroid diseases and may indicate broader implications for healthier aging in the general population. The scientific community and investors alike are taking note of these developments, as reflected in the stock’s upward movement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.